Alzheimer's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Alzheimer's Disease, including details on diagnosis, memory loss, heredity, treatment, medication.

Volume 5 (2008), Issue 5 (May)

1. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators.
   FASEB J, 22(5): 1296-305. [Abstract] [Full-text]
2. Determining care management activities associated with mastery and relationship strain for dementia caregivers.
   J Am Geriatr Soc, 56(5): 891-7. [Abstract] [Full-text]
3. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes.
   J Am Geriatr Soc, 56(5): 847-53. [Abstract] [Full-text]
4. Do financial incentives of introducing case mix reimbursement increase feeding tube use in nursing home residents?
   J Am Geriatr Soc, 56(5): 887-90. [Abstract] [Full-text]
5. Alzheimer amyloid-beta peptides block the activation of C/EBPbeta and C/EBPdelta in glial cells.
   Biochem Biophys Res Commun, 370(4): 619-22. [Abstract] [Full-text]
6. Protective effects of NSAIDs on the development of Alzheimer disease.
   Neurology, 70(19): 1672-7. [Abstract] [Full-text]
7. Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors.
   Neurology, 70(19): 1836-41. [Abstract] [Full-text]
8. APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease.
   Neurology, 70(19): 1842-9. [Abstract] [Full-text]
9. Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype.
   Neurology, 70(19): 1850-7. [Abstract] [Full-text]
10. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study.
    Neurology, 70(19): 1664-71. [Abstract] [Full-text]
11. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology.
    Neurology, 70(19): 1795-802. [Abstract] [Full-text]
12. Education, cognitive function, and severity of neuropathology in Alzheimer disease.
    Neurology, 70(19): 1732-9. [Abstract] [Full-text]
13. Atrophy rates accelerate in amnestic mild cognitive impairment.
    Neurology, 70(19): 1740-52. [Abstract] [Full-text]
14. Specific reactivity of mild/severe Alzheimer's disease patient's sera to antibody against Abeta1-40 epitope 17-21.
    Acta Neurol Scand, 117(6): 404-8. [Abstract] [Full-text]
15. Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease.
    J Neurosci, 28(19): 5007-17. [Abstract] [Full-text]
16. Altered fMRI activation during mental rotation in those at genetic risk for Alzheimer disease.
    Neurology, 70(20): 1898-904. [Abstract] [Full-text]
17. Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease.
    Proc Natl Acad Sci U S A, 105(19): 6813-8. [Abstract] [Full-text]
18. Pathogenesis of autoimmune diseases: antibodies against transglutaminase, peptidylarginine deiminase and protein-bound citrulline in primary Sjögren's syndrome, multiple sclerosis and Alzheimer's disease.
    Scand J Immunol, 67(6): 626-31. [Abstract] [Full-text]
19. Serum leptin levels are higher in females affected by frontotemporal lobar degeneration than Alzheimer's disease.
    J Neurol Neurosurg Psychiatry, 79(6): 712-5. [Abstract] [Full-text]
20. Successful ageing in adversity: the LASER-AD longitudinal study.
    J Neurol Neurosurg Psychiatry, 79(6): 641-5. [Abstract] [Full-text]
21. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline.
    J Neurol Neurosurg Psychiatry, 79(6): 630-5. [Abstract] [Full-text]
22. Current and future therapy in Alzheimer's disease.
    Fundam Clin Pharmacol, 22(3): 265-74. [Abstract] [Full-text]
23. Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation.
    Proc Natl Acad Sci U S A, 105(20): 7327-32. [Abstract] [Full-text]
24. A luteinizing hormone receptor intronic variant is significantly associated with decreased risk of Alzheimer's disease in males carrying an apolipoprotein E epsilon4 allele.
    BMC Med Genet, 9: 37. [Abstract] [Full-text]
25. Impairment of spatial memory consolidation in APP(751SL) mice results in cue-guided response.
    Neurobiol Aging, 29(7): 1011-21. [Abstract] [Full-text]
26. Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease.
    Neurobiol Aging, 29(7): 961-8. [Abstract] [Full-text]
27. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease.
    J Neurosci, 28(22): 5784-93. [Abstract] [Full-text]

© 2004-2008 Alzheimer's Disease Research Today. All Rights Reserved.